-
1
-
-
34548397224
-
Molecular mechanisms of diabetic nephropathy and its therapeutic intervention
-
PMID:17691932
-
Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8: 952-9; PMID:17691932; http://dx.doi.org/10.2174/ 138945007781386884
-
(2007)
Curr Drug Targets
, vol.8
, pp. 952-959
-
-
Yamagishi, S.1
Fukami, K.2
Ueda, S.3
Okuda, S.4
-
2
-
-
65649098711
-
Therapeutic strategies in the treatment of diabetic nephropathy-a translational medicine approach
-
PMID:19275608
-
Shah IM, Mackay SP, McKay GA. Therapeutic strategies in the treatment of diabetic nephropathy-a translational medicine approach. Curr Med Chem 2009; 16:997-1016; PMID:19275608; http://dx.doi. org/10.2174/092986709787581897
-
(2009)
Curr Med Chem
, vol.16
, pp. 997-1016
-
-
Shah, I.M.1
Mackay, S.P.2
McKay, G.A.3
-
3
-
-
55249114365
-
Diabetic nephropathy: Important pathophysiologic mechanisms
-
PMID:18994672
-
Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008; 82(Suppl 1):S75-9; PMID:18994672; http://dx.doi.org/10.1016/j.diabres.2008.09.042
-
(2008)
Diabetes Res Clin Pract
, vol.82
, Issue.SUPPL. 1
-
-
Soldatos, G.1
Cooper, M.E.2
-
4
-
-
33646429192
-
Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy
-
PMID: 16679697
-
Suzuki D, Toyoda M, Yamamoto N, Miyauchi M, Katoh M, Kimura M, et al. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 2006; 45:435-41; PMID: 16679697; http://dx.doi.org/10.2169/internalmedicine. 45.1557
-
(2006)
Intern Med
, vol.45
, pp. 435-441
-
-
Suzuki, D.1
Toyoda, M.2
Yamamoto, N.3
Miyauchi, M.4
Katoh, M.5
Kimura, M.6
-
5
-
-
44449132702
-
Role of AGEs in diabetic nephropathy
-
PMID:18473844
-
Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946-52; PMID:18473844; http://dx.doi.org/ 10. 2174/138161208784139710
-
(2008)
Curr Pharm Des
, vol.14
, pp. 946-952
-
-
Fukami, K.1
Yamagishi, S.2
Ueda, S.3
Okuda, S.4
-
6
-
-
0035135246
-
Advanced glycation end-products: A review
-
PMID:11270668
-
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44:129-46; PMID:11270668; http://dx.doi.org/10. 1007/s001250051591
-
(2001)
Diabetologia
, vol.44
, pp. 129-146
-
-
Singh, R.1
Barden, A.2
Mori, T.3
Beilin, L.4
-
7
-
-
44449132702
-
Role of AGEs in diabetic nephropathy
-
PMID:18473844
-
Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946-52; PMID:18473844; http://dx.doi.org/ 10. 2174/138161208784139710
-
(2008)
Curr Pharm Des
, vol.14
, pp. 946-952
-
-
Fukami, K.1
Yamagishi, S.2
Ueda, S.3
Okuda, S.4
-
8
-
-
0037406905
-
Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy
-
PMID:12707408
-
Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14:1383-95; PMID:12707408; http://dx.doi.org/10. 1097/01.ASN.0000065100.17349.CA
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 1383-1395
-
-
Wendt, T.1
Tanji, N.2
Guo, J.3
Hudson, B.I.4
Bierhaus, A.5
Ramasamy, R.6
-
9
-
-
0035153678
-
Advanced glycation end products, their receptors and diabetic angiopathy
-
PMID:11694852
-
Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27:535-42; PMID:11694852
-
(2001)
Diabetes Metab
, vol.27
, pp. 535-542
-
-
Wautier, J.L.1
Guillausseau, P.J.2
-
10
-
-
27744453362
-
Understanding RAGE, the receptor for advanced glycation end products
-
(Berl) PMID:16133426
-
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83:876-86; PMID:16133426; http:// dx.doi.org/10.1007/s00109-005- 0688-7
-
(2005)
J Mol Med
, vol.83
, pp. 876-886
-
-
Bierhaus, A.1
Humpert, P.M.2
Morcos, M.3
Wendt, T.4
Chavakis, T.5
Arnold, B.6
-
11
-
-
0028068046
-
Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
-
PMID: 7918300
-
Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14:1521-8; PMID: 7918300; http://dx.doi.org/10.1161/ 01.ATV.14.10. 1521
-
(1994)
Arterioscler Thromb
, vol.14
, pp. 1521-1528
-
-
Schmidt, A.M.1
Hori, O.2
Brett, J.3
Yan, S.D.4
Wautier, J.L.5
Stern, D.6
-
12
-
-
3042637228
-
Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy
-
PMID:15224502
-
Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23:129-34; PMID:15224502
-
(2003)
Int J Clin Pharmacol Res
, vol.23
, pp. 129-134
-
-
Yamagishi, S.1
Takeuchi, M.2
Inagaki, Y.3
Nakamura, K.4
Imaizumi, T.5
-
13
-
-
63049117088
-
Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets
-
PMID:19149535
-
Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr Drug Targets 2009; 10:42-50; PMID:19149535; http://dx. doi.org/10.2174/ 138945009787122905
-
(2009)
Curr Drug Targets
, vol.10
, pp. 42-50
-
-
Sourris, K.C.1
Forbes, J.M.2
-
14
-
-
0035856980
-
Biochemistry and molecular cell biology of diabetic complications
-
PMID:11742414
-
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-20; PMID:11742414; http://dx.doi.org/10. 1038/414813a
-
(2001)
Nature
, vol.414
, pp. 813-820
-
-
Brownlee, M.1
-
15
-
-
17144391517
-
Agents in development for the treatment of diabetic nephropathy
-
PMID: 15833059
-
Fukami K, Cooper ME, Forbes JM. Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2005; 14:279-94; PMID: 15833059; http://dx.doi.org/10.1517/13543784.14.3. 279
-
(2005)
Expert Opin Investig Drugs
, vol.14
, pp. 279-294
-
-
Fukami, K.1
Cooper, M.E.2
Forbes, J.M.3
-
16
-
-
76649145110
-
Advanced glycation end-products: Implications for diabetic and nondiabetic nephropathies
-
PMID:19932633
-
Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C, D'Agati VD, Schmidt AM, et al. Advanced glycation end-products: implications for diabetic and nondiabetic nephropathies. Diabetes Metab 2010; 36:1-10; PMID:19932633; http://dx.doi.org/10.1016/j.diabet. 2009.06.005
-
(2010)
Diabetes Metab
, vol.36
, pp. 1-10
-
-
Daroux, M.1
Prévost, G.2
Maillard-Lefebvre, H.3
Gaxatte, C.4
D'Agati, V.D.5
Schmidt, A.M.6
-
17
-
-
0037374652
-
New therapies for advanced glycation end product nephrotoxicity: Current challenges
-
PMID:12612951
-
Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41(Suppl 1):S42-7; PMID:12612951; http://dx.doi.org/10.1053/ajkd.2003.50083
-
(2003)
Am J Kidney Dis
, vol.41
, Issue.SUPPL. 1
-
-
Williams, M.E.1
-
18
-
-
72749121317
-
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression
-
PMID: 19635564
-
Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61:34-9; PMID: 19635564; http://dx.doi.org/10.1016/j.phrs.2009.07. 004
-
(2010)
Pharmacol Res
, vol.61
, pp. 34-39
-
-
Matsui, T.1
Yamagishi, S.2
Takeuchi, M.3
Ueda, S.4
Fukami, K.5
Okuda, S.6
-
19
-
-
73949118948
-
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
-
PMID: 20026306
-
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391:1405-8; PMID: 20026306; http://dx.doi.org/10.1016/j.bbrc.2009.12. 075
-
(2010)
Biochem Biophys Res Commun
, vol.391
, pp. 1405-1408
-
-
Ishibashi, Y.1
Matsui, T.2
Takeuchi, M.3
Yamagishi, S.4
-
20
-
-
67349131842
-
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation
-
PMID:19460355
-
Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2009; 385:269-72; PMID:19460355; http://dx.doi.org/ 10.1016/j.bbrc.2009.05.061
-
(2009)
Biochem Biophys Res Commun
, vol.385
, pp. 269-272
-
-
Matsui, T.1
Yamagishi, S.2
Takeuchi, M.3
Ueda, S.4
Fukami, K.5
Okuda, S.6
-
21
-
-
33947386181
-
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
-
PMID:17343760
-
Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6:9; PMID:17343760; http://dx.doi. org/10.1186/1475-2840-6-9
-
(2007)
Cardiovasc Diabetol
, vol.6
, pp. 9
-
-
Humpert, P.M.1
Djuric, Z.2
Kopf, S.3
Rudofsky, G.4
Morcos, M.5
Nawroth, P.P.6
-
22
-
-
33947408459
-
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
-
PMID:16969649
-
Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49:2756-62; PMID:16969649; http://dx.doi.org/10.1007/s00125- 006-0394-1
-
(2006)
Diabetologia
, vol.49
, pp. 2756-2762
-
-
Tan, K.C.1
Shiu, S.W.2
Chow, W.S.3
Leng, L.4
Bucala, R.5
Betteridge, D.J.6
-
23
-
-
9244247342
-
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy
-
PMID:15546182
-
Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR, Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15:1174-81; PMID:15546182; http://dx.doi.org/10.1021/bc0499127
-
(2004)
Bioconjug Chem
, vol.15
, pp. 1174-1181
-
-
Patri, A.K.1
Myc, A.2
Beals, J.3
Thomas, T.P.4
Bander, N.H.5
Baker Jr., J.R.6
-
24
-
-
17644395605
-
Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting
-
PMID:15848007
-
Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005; 295:221-33; PMID:15848007; http://dx.doi.org/10.1016/j.ijpharm. 2005.01.026
-
(2005)
Int J Pharm
, vol.295
, pp. 221-233
-
-
Bhadra, D.1
Yadav, A.K.2
Bhadra, S.3
Jain, N.K.4
-
25
-
-
60149100143
-
Targeting cancer cells with biotin-dendrimer conjugates
-
PMID: 18550227
-
Yang WJ, Cheng YY, Xu TW, Wang XY, Wen LP. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 2009; 44:862-8; PMID: 18550227; http://dx.doi.org/10.1016/j.ejmech.2008. 04.021
-
(2009)
Eur J Med Chem
, vol.44
, pp. 862-868
-
-
Yang, W.J.1
Cheng, Y.Y.2
Xu, T.W.3
Wang, X.Y.4
Wen, L.P.5
-
26
-
-
77951997577
-
Cancer Therapy Based on Nanomaterials and Nanocarrier Systems
-
Qiao WL, Wang BC, Wang YZ, Yang LC, Zhang YQ, Shao PY. Cancer Therapy Based on Nanomaterials and Nanocarrier Systems. J Nanomater 2010; http://dx.doi. org/10.1155/2010/796303
-
(2010)
J Nanomater
-
-
Qiao, W.L.1
Wang, B.C.2
Wang, Y.Z.3
Yang, L.C.4
Zhang, Y.Q.5
Shao, P.Y.6
-
27
-
-
67349117682
-
Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions
-
PMID:19427582
-
Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009; 60:24-32; PMID:19427582; http://dx.doi.org/10. 1016/j.phrs.2009.02.002
-
(2009)
Pharmacol Res
, vol.60
, pp. 24-32
-
-
Balakumar, P.1
Arora, M.K.2
Ganti, S.S.3
Reddy, J.4
Singh, M.5
-
28
-
-
35348922424
-
Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes
-
PMID:17653212
-
Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007; 106:S54- 60; PMID:17653212; http://dx.doi.org/10.1038/sj.ki. 5002387
-
(2007)
Kidney Int Suppl
, vol.106
-
-
Coughlan, M.T.1
Forbes, J.M.2
Cooper, M.E.3
-
29
-
-
35548975242
-
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy
-
PMID:17823506
-
Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27:605-14; PMID:17823506; http://dx.doi.org/ 10.1159/000108104
-
(2007)
Am J Nephrol
, vol.27
, pp. 605-614
-
-
Williams, M.E.1
Bolton, W.K.2
Khalifah, R.G.3
Degenhardt, T.P.4
Schotzinger, R.J.5
McGill, J.B.6
-
30
-
-
23744516038
-
Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: A rational approach to second-generation Amadorin design
-
PMID:16037307
-
Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 2005; 1043:793- 806; PMID:16037307; http://dx.doi.org/10.1196/ annals.1333.092
-
(2005)
Ann N Y Acad Sci
, vol.1043
, pp. 793-806
-
-
Khalifah, R.G.1
Chen, Y.2
Wassenberg, J.J.3
-
31
-
-
72749121317
-
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression
-
PMID: 19635564
-
Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61:34-9; PMID: 19635564; http://dx.doi.org/10.1016/j.phrs.2009.07. 004
-
(2010)
Pharmacol Res
, vol.61
, pp. 34-39
-
-
Matsui, T.1
Yamagishi, S.2
Takeuchi, M.3
Ueda, S.4
Fukami, K.5
Okuda, S.6
-
32
-
-
37249065845
-
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression
-
PMID:17560613
-
Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008; 75: 130-4; PMID:17560613; http://dx.doi.org/10.1016/j. mvr.2007.05.001
-
(2008)
Microvasc Res
, vol.75
, pp. 130-134
-
-
Yamagishi, S.1
Matsui, T.2
Nakamura, K.3
Inoue, H.4
Takeuchi, M.5
Ueda, S.6
-
33
-
-
0032685198
-
Magnetic core-shell particles: Preparation of magnetite multilayers on polymer latex microspheres
-
Deerfield Beach Fla
-
Caruso F, Susha AS, Giersig M, Mohwald H. Magnetic core-shell particles: preparation of magnetite multilayers on polymer latex microspheres. Adv Mater (Deerfield Beach Fla) 1999; 11:950-3; http://dx.doi. org/10.1002/(SICI)1521- 4095(199908)11:11,950:: AID-ADMA950.3.0.CO;2-T
-
(1999)
Adv Mater
, vol.11
, pp. 950-953
-
-
Caruso, F.1
Susha, A.S.2
Giersig, M.3
Mohwald, H.4
-
34
-
-
0035908572
-
Multilayer assemblies of silicaencapsulated gold nanoparticles on decomposable colloid templates
-
Deerfield Beach Fla
-
Caruso F, Spasova M. Multilayer assemblies of silicaencapsulated gold nanoparticles on decomposable colloid templates. Adv Mater (Deerfield Beach Fla) 2001; 13:1090-4; http://dx.doi.org/10.1002/1521- 4095(200107)13:14,1090::AID- ADMA1090.3.0. CO;2-H
-
(2001)
Adv Mater
, vol.13
, pp. 1090-1094
-
-
Caruso, F.1
Spasova, M.2
-
35
-
-
0037419891
-
A method for making inorganic and hybrid (organic/inorganic) fibers and vesicles with diameters in the submicrometer and micrometer range via sol-gel chemistry and electrically forced liquid jets
-
PMID:12553802
-
Larsen G, Velarde-Ortiz R, Minchow K, Barrero A, Loscertales IG. A method for making inorganic and hybrid (organic/inorganic) fibers and vesicles with diameters in the submicrometer and micrometer range via sol-gel chemistry and electrically forced liquid jets. J Am Chem Soc 2003; 125:1154-5; PMID:12553802; http://dx.doi.org/10.1021/ja028983i
-
(2003)
J Am Chem Soc
, vol.125
, pp. 1154-1155
-
-
Larsen, G.1
Velarde-Ortiz, R.2
Minchow, K.3
Barrero, A.4
Loscertales, I.G.5
-
36
-
-
0035914220
-
Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-coglycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers
-
PMID:11578739
-
Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-coglycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001; 76:239-54; PMID:11578739; http://dx. doi.org/10.1016/S0168-3659(01)00440-0
-
(2001)
J Control Release
, vol.76
, pp. 239-254
-
-
Mu, L.1
Feng, S.S.2
-
38
-
-
34249894977
-
Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
-
PMID:17509712
-
Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007; 120:18-26; PMID:17509712; http://dx.doi.org/ 10.1016/j.jconrel. 2007.03.012
-
(2007)
J Control Release
, vol.120
, pp. 18-26
-
-
Kocbek, P.1
Obermajer, N.2
Cegnar, M.3
Kos, J.4
Kristl, J.5
|